The University of Chicago Header Logo

Connection

Mark W. Lingen to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Mark W. Lingen has written about Dose-Response Relationship, Drug.
Mark W. Lingen
Connection Strength
0.044
Dose-Response Relationship, Drug
  1. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.031
  2. Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin. J Cell Physiol. 2006 May; 207(2):553-61.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.